Plain-language explainers on how cardiovascular and metabolic treatments work, what trial results actually mean, and what gets presented at the major cardiology meetings.
Written for people following the field without a specialist background.
2026 dates, embargo rules and late-breaker timing for ACC, ESC, AHA, ADA, EASD, ObesityWeek and AASLD, plus verified ACC and ESC 2026 examples.
Read more →What competitive intelligence means in cardiovascular and metabolic drug development, who uses it, what it covers and common pitfalls, with 2026 examples.
Read more →Finerenone (Kerendia) now has heart failure and CKD labels. Trial evidence, Q3 2026 sales and rivals such as spironolactone and vicadrostat.
Read more →